These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29122917)

  • 1. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 2. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
    Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
    Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
    Mok J; Kang H; Koh WJ; Jhun BW; Yim JJ; Kwak N; Lee T; Kang B; Jeon D
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31285308
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R; Geiter LJ; Wells CD; Gao M; Cirule A; Xiao H
    N Engl J Med; 2015 Jul; 373(3):291-2. PubMed ID: 26176402
    [No Abstract]   [Full Text] [Related]  

  • 6. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 7. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 8. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Chang KC; Leung EC; Law WS; Leung WM; Tai LB; Lee SN; Lam FM; Chau CH; Mok TY; Yew WW; Leung CC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29650556
    [No Abstract]   [Full Text] [Related]  

  • 9. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
    Seung KJ; Khan P; Franke MF; Ahmed S; Aiylchiev S; Alam M; Putri FA; Bastard M; Docteur W; Gottlieb G; Hewison C; Islam S; Khachatryan N; Kotrikadze T; Khan U; Kumsa A; Lecca L; Tassew YM; Melikyan N; Naing YY; Oyewusi L; Rich M; Wanjala S; Yedilbayev A; Huerga H; Mitnick CD
    Clin Infect Dis; 2020 Jul; 71(2):415-418. PubMed ID: 31676905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 16. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
    Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to new drug development in respiratory disease.
    Brigden G; du Cros P; Wong S
    Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
    [No Abstract]   [Full Text] [Related]  

  • 20. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.